Extremely variable clinic and genetic features characterize mitochondrial encephalomyopathy (MEM). Pathogenic mitochondrial DNA (mtDNA) defects can be divided into large-scale rearrangements and single point mutations. Clinical manifestations become evident when a threshold percentage of the total mtDNA is mutated. In some MEM, the "mutant load" in an affected tissue is directly related to the severity of the phenotype. However, the clinical phenotype is not simply a direct consequence of the relative abundance of mutated mtDNA. Other factors, such as nuclear background, can contribute to the disease process, resulting in a wide range of phenotypes caused by the same mutation. Using Affymetrix oligonucleotide cDNA microarrays (HG-U133A), we studied the gene expression profile of muscle tissue biopsies obtained from 12 MEM patients [4 common 4977 bp deleted mtDNA and 8 A3243G: 4 progressive external ophthalmoplegia (PEO) and 4 mitochondrial myopathy, encephalopathy, lactic cidosis, and stroke-like episodes syndrome (MELAS) phenotypes] compared with agematched healthy individuals. We found several differentially expressed genes: 35 were markedly up-regulated in the mtDNA macro-deletion group (vs. the control group) and 4 decreased; 56 genes were dysregulated in A3243G-related disorders (53 down-regulated in PEO and 3 upregulated in MELAS). Finally, 12 genes were similarly regulated in the majority of the MEM patients under study. Amongst these, we identified an increased expression of genes related to the metabolism of the amino groups, as well as of several genes involved in genetic information processing. Moreover, few genes were similarly decreased in MEM patients vs. the control group. Real-time PCR demonstrated excellent reproducibility of the microarray-based findings. The observed expression changes are likely to represent a molecular signature for mitochondrial disorders. Furthermore, the differential expression profile of MELAS A3243G vs. PEO A3243G may support a role of nuclear background in contributing to these different clinical phenotypes. MEM Page 1 of 30 (page number not for citation purposes) microarray data are available from GEO database (http://www.ncbi.nlm.nih.gov/geo/) with the accession number: GSE1462.
"Bank of DNA, nerve and muscle tissues" (GTF02008). The diagnosis of MEM was based on commonly accepted clinical and laboratory criteria (12) . Histology and histochemical analysis of muscle biopsies showed a variable number of COX-negative, ragged red fibers in all mitochondrial patients. Diagnostic criteria for the distinctive clinical MEM syndromes followed those defined by Rowland (13) for Kearns-Sayre Syndrome and PEO, revised by Moraes (14) , and by Pavlakis (15) for MELAS. The muscle samples were also subjected to spectrophotometric determination of respiratory chain enzyme activities (Table 1) as described previously (16) . Each patient signed an informed consent, approved by our Institutional IRB, at the time of muscle biopsy that specifies the use of part of his/her muscle tissue for research purposes.
RNA extraction, labeling, and hybridization
Frozen tissue was stored at -80°C. Total RNA was purified from 40 mg of tissue, using the EUROZol Kit (EuroClone Ltd.) following the manufacturer's instructions. Total RNA (5 µg) was reverse-transcribed with a cDNA synthesis kit in the presence of SuperScript II RT (Invitrogen-Life Technologies, Inc.) and an oligo dT-T7 primer (Affymetrix Inc., Santa Clara, CA). After phenol/chloroform extraction and ethanol precipitation, the cDNA pellet was airdried and resuspended in 12 µl of diethyl pyrocarbonate-treated water and quantified by spectrophotometer measurement. An aliquot of each sample was conserved for gel electrophoresis and for inspection of RNA quality (i.e., 28S:18S RNA ratio). Ten microliters were used for the in vitro transcription (IVT) amplification reaction, in the presence of biotinylated nucleotides (Enzo Biochem Inc.). Labeled cRNA (15 µg) was fragmented by incubation at 94°C for 35 min in fragmentation buffer (GeneChip ® Sample Cleanup, Qiagen) and the fragmented cRNA was then hybridized competitively against the Affymetrix HG-U133A oligonucleotide array, containing 22,283 spots representative of full-length known human genes and clustered ESTs. Hybridization occurred at 47°C overnight. The arrays were scanned using a GeneArray ® 2500 scanner (Affymetrix) and analyzed using MicroArray Suite 5.0 (Affymetrix) All experiments were validated after direct measures of cRNA quality: 5′:3′ ratio for β-actin and for GAPDH (determined from Affymetrix chip hybridization analysis) are indirect indicators of overall RNA preservation. The default parameters were used for the statistical algorithm and for probe set scaling. The target intensity was set to 1,000 to normalize expression levels across all samples.
Data analysis
The microarray data derive from four different groups: pathology A (A3243G-MELAS), pathology B (A3243G-PEO), pathology C (common 4977-bp mtDNA macrodeletion), and control group D. Each population consists of four RNA profiling samples, excluding control group that has three samples. Our analysis is based on three outputs of Affymetrix GeneChip arrays: "Signal" (expression level), "Difference" and "Detection" (absent/present) calls were generated for each gene. Subsequent analyses used Microsoft Excel (Microsoft Office ® package) and in-house analytical and statistical tools. Mean values from each control sample were used when comparing different MEM categories. Ratios were generated for the expression of each gene in each matched mitochondrial patient/control pair.
For Filter 1, data sets were excluded if 1) the Detection was absent in all subjects or was absent in almost three out of four, and one was called marginal; 2) the Difference call was not changed (NC) in all comparisons; or 3) it was marked as AFFX internal control.
For Filter 2, inside each population only probes with "internal" homogeneity (2/4 identical detections are considered for groups A, B, and C; 2/3 are considered for group D) are selected to avoid bias depending on experimental limits, partly attributed to inter-patient variability and partly to tissue heterogeneity (17) . Marginal detections are included in the analysis. After this selection, four categories (A vs. B, A vs. D, B vs. D, C vs. D) are analyzed. For each category X vs. Y, with X = {A, B, C} and Y = {B, D}, we obtained a NxM matrix. N is the pairwise intersection of at least 1 probe between X and Y (N is ~13% of Affymetrix microarray probe set), and M is the product of the number of chips in X for the number of chips in Y (M=12 or M=16). Matrix X vs. Y contains all the possible signal log ratio of the expression level in X and Y chips. The matrix is further reduced: rows are selected in order to obtain a 70% homogeneity in sign and mean [abs (signal log ratio)] >=1; columns are analyzed using the principal component analysis (PCA) to extrapolate only independent components and decrease interpatient variability (18) . After PCA, X vs. Y is a six-column matrix for all the four categories, while the number of rows depends on the difference between the populations (X, Y) considered. Hierarchical cluster analysis (19, 20) is applied to X vs. Y using the furthest distance method to organize probes into groups with a similar level of expression. Finally, we defined genes with candidate changes in MEM patients as genes for which (Filter 3): 1) fold change was >2.5, 2) the difference in the mean group/control ratio from a value of 100, and 3) there were no negative mean average difference values in any of the groups (because these represented low-level expression and were therefore of low confidence). Some genes with fold change <2.5 were nevertheless regarded as important candidates because they were accompanied by an increase in Difference Calls in all three comparisons (each pathological group vs. controls).
Every probe has been associated with its NCBI identifier, tissue of expression, and gene name in order to correlate every cluster with characteristics determining a biological homogeneity. Matlab software was used to develop and perform the calculation routines. Functional grouping of genes was based on annotation from LocusLink, OMIM, sequence homology analysis, and literature searches. Finally, gene list generated by microarray analysis was submitted to PathwayAssist (Iobion Informatics, LCC), a software tool that allows for the identification and visualization of pathways, gene regulation networks, and protein interaction maps.
Quantitative real-time PCR analysis
Real-time reverse transcription-polymerase chain reaction (RT-PCR) data were obtained as follows: 1.5 µg of total RNA from each single patient and from each single healthy volunteer was reverse-transcribed by Ready-To-Go according to the manufacturer's recommendations (Amersham Pharmacia Biotech). The generated first-strand cDNA was diluted and used as template for real-time quantitative PCR analysis using Assays-on-Demand TM gene expression products (Applied Biosystems, Foster City, CA). This method uses a mix of unlabeled PCR primers and TaqMan ® MGB probe (FAM TM dye-labeled) in which the target sequence is located within the primer-generated amplicon. The reporter probe has a fluorescent dye on the 5′-end (FAM) and a quencher on the 3′-end (TAMRA). During the extension phase of the PCR amplification, the 5′ exonuclease activity of the Taq DNA polymerase cleaves the probe releasing the fluorescent dye from the quencher. At each cycle of the PCR process, the increase in fluorescence was monitored by an ABI PRISM ® 7700 Sequence Detection System (PerkinElmer/Applied Biosystems). The following gene expression assays were detected: MAOA (Hs00165140_m1), ARG2 (Hs00265750_m1), CDKN1A (Hs00355782_m1), COX7A1 (Hs00156989_m1), CAT (Hs00156308_m1), XPOT (Hs00610636_g1), MLC1SA (Hs00365997_g1), TAF15 (Hs00185844_m1), and RYR3 (Hs00168821_m1). The expression level of the 18S rRNA gene (Hs99999901_s1) was used to normalize for differences in input cDNA. Each gene was profiled separately, but the same pool of cDNA was used for all reactions. For each gene (comprising the 18S), we used commercially available predeveloped TaqMan assays (PE/AB). PCR primers for each gene were designed in adjacent exons and the fluorogenic probe spanning the junction between them. PCR reactions occurred in a volume of 20 µl, in which 1 µl of diluted cDNA solution was used as template for each reaction. The thermal cycling program was first set at 95°C for 10 min, followed by 40 amplification cycles at 95°C for 15 s and 60°C for 1 min.
Western blot analysis of arginase II
To evaluate a putative increase in protein levels, Western blot analysis of arginase II enzyme was performed on the same muscle homogenates. The protein was resolved in a 9.5% SDS-PAGE and was detected with the arginase II-antibody (Santa Cruz Biotechnology, Santa Cruz, CA) at 1:300 dilution. Kidney specimen obtained from a healthy subject was loaded as controls. An estimate of the relative amount was obtained by densitometric analysis of arginase signal normalized to that of myosin heavy chain.
RESULTS

Patients and clinical data
The study was performed using muscle biopsy samples from 12 patients affected by mitochondrial encephalomyopathy. Four patients presented with PEO associated with mitochondrial DNA single macrodeletion on the Southern blot analysis of muscle DNA, four had PEO associated with heteroplasmic A3243G mtDNA mutation, and four were affected by MELAS and carried the same A3243G mtDNA mutation ( Table 1 ). The level of mtDNA heteroplasmy did not differ between the two A3243G-related groups. Muscle samples from three age-matched healthy subjects were used as controls.
Expression profiling
Transcriptional profiling was carried out on muscle tissue biopsies using Affymetrix human HG-U133A GeneChip oligonucleotide arrays. Each array contains 22,283 probe sets corresponding to 18,400 transcripts and variants, including 14,500 well-characterized human genes and other expressed sequence tags (ESTs). Sample labeling, hybridization, and scanning were carried out according to Affymetrix recommendations.
The initial statistical analysis was performed with Affymetrix Microarray Suite 5.0 software to evidence differential pattern profiles in expression levels between profile pairs (Fig. 1) .
Of all probes assayed on the arrays, almost 50% of initial data passed the first significance filter (see Materials and Methods and Fig. 2 ) meeting Affymetrix criteria for being "expressed in at least one sample." Of this group, as described below, 712 probes were significantly "changed in mitochondrial disorders" as compared with controls (second filter). The third significance filter selected genes whose mean expression values differs at least 2.5-fold of the respective comparisons and with a difference of at least 100 in the mean group/control ratio. Following this procedure, 114 probes demonstrated significance in the mtDNA-related disorders: 53 were identified as up-regulated and 61 as down-regulated (Table 2) .
When plotted in terms of fold change for the four analyzed groups, these gene expression differences showed a clustered distribution according to disease phenotypes. The profile of all the deregulated genes was visualized in dendrograms using TIGR MultiExperiment Viewer (TMEV) software (http://www.tigr.org). Each dendrogram clusters patients with a similar expression profile into families: the image shows that MELAS A3243G patients cluster together, whereas the clustering algorithm groups PEO A3243G patients and normal controls separately, into two other distinct families (Fig. 3A) . Gene expression analysis confirms the presence of clusters of well-specific changes in the mtDNA common-macrodeleted group ( Fig. 3B and C) identifying two main branches, one predominantly containing the four muscle biopsy specimens and one with all healthy individual samples. The dendrograms show several 2.5-fold up-regulated genes in the majority of MEM patients.
To verify whether the observed differences are involved in common cellular pathways, we assigned each gene to functional categories (Fig. 4) using the Gene Ontology database (http://www.geneontology.org).
Genes associated with substrate and energy metabolism, mainly belonging to the urea-cycle and fatty acid metabolism, represented the largest single functional group, since they accounted for 24.3% of all the genes with significant expression change in the MEM groups.
Elements controlling genetic processing (13.1%) and involved in cell-cycle regulation (9.3%) were the other two major functional categories showing significant changes. A functional association of 23 genes not included in the mentioned categories revealed 3 other groups, namely those involved in protein biosynthesis (5.6%), neuromuscular development (8.4%), and signal transduction (7.5%). These results are summarized in Table 2 .
Furthermore, gene clustering identifies a relatively large group of genes without a precisely characterized function (18.7%): we mapped their genomic location using the NCBI UniSTS database as detailed in Table 3 . Interestingly, some of these candidate mitochondrial pathogenesis-related genes clustered to the chromosomal region 9q21-34.
Real-time PCR was not only used to confirm the abnormal gene expression profiles detected by microarray analysis but also to better define "fold change" variations using a more sensible approach. The expression of nine genes (MAOA, ARG2, CDKN1A, COX7A1, CAT, XPOT, MLC1SA, TAF15, and RYR3), representing major functional gene families and demonstrating changes in disease phenotypes, was measured by RT-PCR (Figs. 5 and 6). By the same method, in addition to the 15 muscle tissue biopsies already studied, we tested other 5 samples to obtain 5 samples for each category. This approach showed mean fold changes in expression levels directionally similar to those determined by microarray analysis. Overall, "fold change" was lower when using microarrays approach as compared with real-time PCR, as previously observed (21) .
The RT-PCR dosage of COX7A1 transcript level confirmed its up-regulation observed by U133A analysis. The same change was also observed by microarray analysis in other 13 nuclear genes encoding various subunits of the mitochondrial respiratory chain complexes (Table 2) .
Amongst the genes assayed by RT-PCR, ARG2, and CDKN1A genes are commonly upregulated in all subjects with a mitochondrial encephalomyopathy (P<0.01, Student's t test). Their expression patterns mirrored the microarray results. RT-PCR also confirmed the differential expression of genes encoding key components of the cell cycle in subjects with MELAS A3243G .
Only in one case (CAT gene coding for catalase, a tetrameric hemoprotein that detoxifies hydrogen peroxide), the concordance between the array and the RT-PCR data was not so high. Yet, the marked up-regulation of CAT expression (as shown by microarrays) was observed both in MELAS and in PEO (Fig. 5B) , supporting a role of this gene in mitochondrial pathogenesis of A3243G-related disorders. RT-PCR data conformed that ryanodine receptor 3 (RYR3), a gene coding for an enzyme regulating the Ca 2+ transport in the oxidative stress condition (22) , is increased in each of MELAS A3243G subjects and partially down-expressed in PEO A3243G subjects (Fig. 5B) . Finally, the consistently increased levels of TAF15, belonging to the TFIID complex (a transcription factor coordinating the activity of the RNA-polymerase II) (23) was detected using both microarrays and RT-PCR, suggesting the involvement of the mechanism of transcription-mediated DNA repair in both A3243G disorders. Interestingly, the other three genes coding for transcription elements involved in polymerase II regulation were downregulated in PEO A3243G muscle biopsies.
Based on stringent statistical analysis tools used for defining differences across groups and the functional pathway analysis, the differential pattern of expression observed in MEM seems to be part of an overall program of changes (Fig. 7B ). The main common feature is represented by a possible adaptive overall expansion of several metabolic functions in muscle tissues; however, changes in other major gene families may contribute to the phenotypic diversity of the investigated mtDNA-related disorders.
DISCUSSION
To investigate the influence of nuclear genes on the expression of established mtDNA mutations, we used global expression profiling. In the present study, we characterized the gene expression of muscle tissue of MEM patients carrying either a large mtDNA deletion or the A3243G mutation and compared it to that of microarray data from age-matched healthy controls.
When compared with normal subjects, a differential gene expression profiling was identified in the muscle tissue of all the investigated mtDNA disorders: part of these changes is common to all MEM categories, while others seem to be specific to a given phenotype. The most commonly dysregulated genes are involved in substrate and energy metabolism (several of which belong to amino group metabolism), in cell-cycle regulation and protein biosynthesis.
Commonly differentially regulated genes in mtDNA-related disorders vs. controls
Our data suggest that a metabolic complex candidate for the coordinated deregulation in mitochondrial disease would include the arginine-dependent network and its possible coactivators and/or co-repressors that could simultaneously link multiple pathways. In the majority of our patients we have observed the deregulation of several genes involved in the metabolism of the amino groups and regulation of the urea-genesis (including ARG2, ASNS, and ASS).
The urea cycle is directly involved in the metabolism of arginine, and the final catabolic step is accomplished by arginase. Arginase exists in two isoenzymes: ARG1, with an exclusively hepatic expression, and ARG2, represented in extra-hepatic tissues such as kidney and brain. ARG2 is an enzyme with mitochondrial localization and is characterized by low expression (24); ARG2 prevailing function is to produce ornithine from arginine. Arginine plays also an important physiological role in the synthesis of other polyamines, such as nitric oxide (NO) and creatine (25). A lower-than-normal arginine concentration caused by ARG2 overexpression could redirect NO toward peroxynitrite, which, in turn, acts as a second messenger that can trigger apoptosis by inducing mitochondrial membrane permeabilization. Indeed, it has been shown that NO and its toxic metabolite peroxynitrite can inhibit the mitochondrial respiratory chain, leading to energy failure (26). A low arginine amount could determine a reduction in argininosuccinasic activity, contributing some of the characterizing aspects of the mitochondrial pathogeneses. Consistently, in argininosuccinic aciduria, a mitochondrial disease characterized by mental retardation, epilepsy, and ataxia, a low level of arginine is present in liquor (27) and Larginine e.v. infusion seems to improve cerebral ischemia in MELAS patients in the acute phase of stroke (28). Moreover, arginine has an anti-oxidant activity and promotes the production of human growth factor (HGF). Therefore, chronic arginine deficiency could reduce the HGF plasmatic levels and influence the normal development, accounting for the low stature often observed in mitochondrial disorders. Western blot analysis confirmed the high-level expression of arginase II protein in muscle sample homogenates obtained from mtDNA-damaged patients (Fig. 7A) . Furthermore, we examined the entire pathway involving the arginine metabolism: 6 enzymes did not reach cutoffs but were up-regulated with an average fold increase of >1.4. Among these enzymes, a particular increase was observed for fumarate hydratase (1.65-fold increase). These findings are consistent with the observation that the entire arginine pathway is altered in a coordinate manner in muscle mtDNA-mutated cells.
Analyses of microarray data also indicate that two cyclin-dependent kinase inhibitor (CDKN) isoform (1A and 1C) genes were up-regulated in all (CDKN1A) or a subgroup (CDKN1C) of MEM patients. The expression of CDKN1A (better known as p21) gene is tightly controlled by p53, through which this protein mediates the cell cycle G1 phase arrest in response to a variety of stress stimuli (29). The CDKN1A protein binds to and inhibits the activity of cyclin-CDK2 or -CDK4 complexes playing essential growth regulation, survival, and anti-apoptotic roles in many human cell types (including muscle tissue). Furthermore, by interacting with the DNA polymerase accessory factor PCNA, CDKN1A plays a regulatory role in the repair of damaged nuclear and mitochondrial DNA (30). Other cell cycle regulators are up-regulated together with CDKN transcripts in MEM muscle: one of them, caspase-8 and FADD-like apoptosis regulator (CFLAR), is a cell survival pathway anti-apoptotic gene, predominantly expressed in muscle (31). CFLAR signal was increased in the majority of the muscle biopsies of MEM patients.
Contradictory data are present in the literature regarding the role of programmed cell death in the pathogenesis of mitochondrial disorders (32, 33). Considering the up-regulation of CFLAR and the down-regulation of other genes involved at different levels in the apoptosis pathway (as well as IGFR2, PTK2, EGFR, and PDE4B), particularly in muscle PEO
A3243G
, apoptosis seems unlikely to play a major role in the pathogenesis of MEM (at least, at the skeletal muscle level).
Gene down-regulation is not a marked feature of MEM muscle. Two exceptions to this observation exist: PEX6, a peroxisomal content and biogenesis factor (34), and MAOA, a molecule with an important enzymatic activity in the catabolism of neurotransmitters (particularly down-regulated in MEM patients with mtDNA common-macrodeletion).
Genes differentially expressed in MELAS
A3243G vs. PEO
A3243G
When comparing muscle tissues from two phenotypically distinct mitochondrial disorders that share the same mtDNA point mutation A3243G, microarray analyses showed a restricted differential profile. Many genes were down-regulated in PEO A3243G muscle biopsies and expressed at normal levels in MELAS A3243G patients.
Noteworthy, some of the differentially expressed genes influence the process of transcription and, in particular, the regulation of RNA-polymerase II activity. Indeed a link between the regulation of the mitochondrial biogenesis/oxidation and RNA-polymerase II-dependent RNA processing has been observed under the physiological adaptive thermogenesis (35). Recent evidence demonstrated that the transcription termination of mitochondrial mRNA might depend on the interaction of specific sequences at the end of the mtDNA heavy chain and RNApolymerase II (36). Initiation of transcription by RNA-polymerase II requires the activities of >70 polypeptides. The complex that coordinates these activities is TFIID, which binds to the core promoter to position the polymerase properly, serves as a scaffold for transcription complex assembly and acts as a channel for regulatory signals. TFIID is composed of the TATA binding protein (TBP) and a group of evolutionarily conserved proteins known as TBP-associated factors (TAF). TAFs may participate in basal transcription, serve as coactivators, function in promoter recognition, or modify general transcription factors to facilitate a complex assembly and transcription initiation. We found TAF15 to be differentially expressed in MELAS A3243G vs. PEO A3243G , both at the microarray and RT-PCR analysis. This gene encodes a subunit of the TFIID complex: by interacting within the RNA-polymerase II, TAF15 modulates cell-cycle progression and gene regulation. Conceivably, an altered expression of RNA-polymerase IIassociated proteins in response to mtDNA impairment could directly lead to changes in the expression of other genes. In fact, it is already known that A3243G-related disease is characterized by an abnormal hyperexpression of genes regulating the transcription process (37) . Moreover, an altered regulation of mtDNA transcription factors such as mtTFA has been observed in MEM (38) . Recent findings using microarray techniques discovered that the expression of key transcription factors relevant for the mitochondrial biogenesis is changed also in other disorders, suggesting the relevance of the respiratory chain complex regulation in the pathophysiology of several human diseases. For instance, the altered expression of a coregulated subset of OXPHOS genes is observable in skeletal muscle tissue in human diabetes (39) and in the progression of a rat model of cardiac heart failure (40).
Another important class of differentially expressed probes comprises genes with a role in the development of neurobiological structures: ARIH2, CRYM, KAL1, and SEMA3C are downregulated in PEO A3243G vs. MELAS A3243G phenotypes. Expression profiling obtained from mtDNA-lacking cells revealed a pattern that supports our results for genes involved in the developing vertebrate central nervous system as well as in the fatty acid metabolism and mitochondria control of Ca 2+ homeostasis (41).
Down-regulation of genes involved in fatty acid oxidation (the major energy source during periods of fasting) seems to characterize only A3243G patients with a PEO phenotype. Recent data suggest that Krüppel-like factors (KLFs) play a key role in the transactivation of the fattyacid metabolism genes induced by prolonged fasting in the skeletal muscle (42) . In our PEO A3243G patients, we observed a decreased expression of genes related to fatty acid metabolism as well as the KLF4, the gene coding for the KLF4. A microarray global gene expression analysis regarding the progression of mitochondrial dysfunction associated with experimental cardiac failure indicated a down-regulation of several genes encoding critical enzymes in fatty acid oxidation (43) . It is fairly likely that a down-regulation of fatty acid oxidation, coupled with respiratory chain deficiency, would lead to increased utilization of proteins as energy source and to extensive protein degradation, a mechanism resulting in progressive myopathy, a process invariably observed in our PEO A3243G patients.
A3243G MELAS vs. PEO muscle biopsies GeneChip analysis also identified a differential expression of the genes involved in the process of detoxification of hydrogen peroxide after oxidative stress: dual specificity phosphatase 1 (DUSP1) and catalase (CAT). When cell respiration is maximally enhanced, catalase is efficiently targeted to the mitochondrial matrix where it presumably functions as scavenger of H 2 O 2 and mitochondrially derived ROS. DUSP1 encodes for a phosphatase that has dual specificity (for tyrosine and threonine residues) and regulates protein degradation by specifically-inactivating mitogen-activated protein kinase (44) . Muscle cells carrying the MELAS A3243G mutation show an increased catalase activity as adaptive response to an increased production of reactive oxygen species (45) .
The RYR3 gene is up-regulated in MELAS A3243G muscle. Ryanodine receptors, such as RYR3, are the channels responsible for the release of Ca 2+ from intracellular stores (sarcoplasmic reticulum) after transduction of many different extracellular stimuli (46) . Though expressed in fetal skeletal muscle, RYR3 mRNA is usually present in brain tissue during the mammalian adult life. RYR 3 up-regulation in MELAS may reflect changes in muscle Ca 2+ homeostasis in this respiratory chain disorder. This finding is consistent with the observation that mtDNA-depleted cells show an enhanced expression of proteins involved in Ca 2+ -RYR released signaling (47) .
Differentially expressed genes in single mtDNA macrodeleted group only
Among differentially expressed genes, only five are down-regulated in the mtDNAmacrodeletion group: they belong to heterogeneous functional categories.
Monoamine oxidase-A (MAOA) has its greater activity in the central and peripheral nervous system, where it drives the enzymatic degradation of biogenic amines such as dopamine, serotonine, and adrenaline. MAOA is a mitochondrial enzyme located in the external membrane. Transgenic mice lacking MAOA activity present a delayed neuromuscular development and hyperammoniemic coma (48) . The MAO-catalyzed oxidation of biogenic amines contributes to the intramitochondrial concentration of H 2 O 2 causing oxidative damage to mtDNA (49) . Two further genes involved in biogenic amine metabolism showed a differential expression profile in the mtDNA-macrodeletion group, namely COMT enzyme (the two COMT probes, 208817_at and 208818_s_at, were increased at 1.59 and 1.46, respectively) and Histidine decarboxylase (probe 207067_s_at), which showed a 2.1-fold increase in expression.
Another down-regulated gene is myosin light chain 1 slow A (MLC1SA), a transcriptional regulator promoting muscle cell proliferation, expressed in both slow-twitch skeletal muscle and nonmuscle tissue. MLC1SA is one of the two phosphorylable regulatory light chains composing the myosin complex (50).
Conversely, mitochondrial translation optimization 1 (MTO1) shows increased expression levels in patients carrying mtDNA macrodeletions. Recently, Li observed that the product of MTO1, a protein ubiquitously present in mitochondria, becomes markedly expressed in cells with high a metabolic demand; MTO1 could play a role in protein biosynthesis acting on the posttranslational modifications of the mitochondrial tRNA (51, 52) . Exportin (XPOT), another RNA modulator, is down-regulated in the mtDNA common-macrodeleted group. The XPOT gene is involved in the control of the efficiency and accuracy of translation and mediates tRNAs nuclear export.
A remarkable increase in several nuclear genes encoding OXPHOS subunits was observed. It should be noted that muscle tissue has a physiological high level of expression of OXPHOS genes. Therefore, it is unlikely that changes exceed the 2.5 threshold level (the cut-off set for all other gene categories). We observed that, comparing the mtDNA macrodeletion group with control subjects all the OXPHOS-related genes are increased by a 1000 factor in "signal" value. The mitochondrial electron transport chain consists of five large enzyme complexes (complexes I-V) situated in the inner mitochondrial membrane that couple oxidation to phosphorylation and provide most of the ATP that is necessary for cell survival. In the mtDNA commonmacrodeletion group, the mRNAs of 14 out of 70 nuclear polypeptides in the five complexes were increased (Fig. 3C) . As previously observed (53) , it is likely that muscle tissue attempts to compensate for OXPHOS defects associated with mtDNA rearrangements by increasing the expression of nuclear-DNA-encoded OXPHOS components (54) . This feature is likely associated with the morphological and histochemical phenotype of the ragged red fibers. It is also possible that these changes are accompanied by an increase in reactive oxygen species as observed whenever dysfunction of the mitochondrial electron transport chain occurs (55) . Generally, muscle tissue seems to redirect metabolism by several strategies, mainly by overexpression of OXPHOS and urea-cycle genes. As in urea-cycle defects, it might be important to control protein intake to maintain a corrected equilibrium balanced ammonia and aminoacid metabolism.
Whereas microarrays identify target genes of interest among thousands of genes, truly quantitative information relies on RT-PCR. To investigate the validity of the array data, the expression levels of nine differentially expressed genes were measured using the TaqMan 5′ nuclease fluorogenic RT-PCR assay. Relative expression levels initially determined with the cDNA microarrays were correlated with the expression levels valued using RT-PCR for each patient sample. The main correlation between the two assays for all genes was high, indicating a good agreement between the two assays for the identification of deregulated genes (Figs. 5 and  6) . A statistical analysis performed on RT-PCR results in the group of MEM patients and controls showed significant differences, suggesting a relevant involvement in mitochondrial pathogenesis.
Today, the molecular pathogenesis of MEM is not supported by clear evidence: since an identical mtDNA mutation can be associated with different clinical outcomes, it is likely that nuclear genetic factors are relevant to this marked phenotypic variability. Our findings, together with literature data, seem to confirm that the clinical phenotypes associated with a mtDNA mutation are also probably modulated by nuclear genetic factors. The observed changes await further confirmation in larger disease groups. It should also be mentioned that, since "fold change" was our filtering criterion, we have excluded genes with subtle expression level differences; these minor changes may also prove to be of potential biological significance.
Possible therapeutic targets
In this study, we present microarray data showing the deregulation of several factors that may inhibit normal cell survival in patients with MEM and could be molecular markers of diagnostic use.
The field of mitochondrial encephalomyopathies has been extensively investigated in the last years resulting in well-defined genetic and biochemical data regarding several aspects of MEM etiopathogenesis. Patients have been largely studied for respiratory chain activities, degrees of mitochondrial proliferation, basic genetics and potentially relevant pathogenetic elements, such as for instance the balance of pro-and anti-apoptotic factors. Rather not surprisingly these previous observations deepen our knowledge regarding these metabolic disorders but left the identification of potential new therapeutic targets largely unattended. From this point of view, it is interesting to note that one of the pathogenic elements raised by the present study (the activation of the arginine cycle) fits well with a recently proposed treatment of the acute phase of stroke in MELAS patients. If this observation will be proved correct, gene expression profiling would prove to be a useful approach to mine new data and hopefully open new perspective for these disorders. Beside genes related to the metabolism of the amino groups, we found that also several other genes involved in genetic information processing are similarly deregulated in the majority of the MEM patients under study and may be useful for the identification of novel therapeutic targets for mitochondrial disorders. . For all investigated genes, we found a good correlation of expression values obtained with the 2 technologies, with the exception of CAT, for which we obtained a higher ratio (MELAS A3243G /normal muscle) using RT-PCR than using microarrays. *Significantly marked differences (P<0.01, Student's t test) from the control group. A significantly less relevant difference (P=0.031, Student's t test) was observed for the XPOT gene. .5% SDS-PAGE and protein extracts was detected using an antibody against the N terminus of Arginase II antigens: one control muscle sample, three affected subjects and a kidney specimen. B) Schematic representation of potential signaling pathways involved in MEM. Pathways were identified by incorporating the microarray results into PathwayAssist. Solid symbol represent genes that are up-regulated in MEM compared with normal skeletal muscle biopsy, open symbols are genes that are down-regulated in affected specimens compared with normal, and gray shaded symbols represent gene that did not show a difference between MEM and normal samples. The protein interaction map confirms that many steps constituting the arginine pathway metabolism are up-regulated in mtDNA-damaged patients (red numbers identify macrodeleted-control comparison, blue numbers distinguish MELAS-PEO comparison).
